Latest TARO reports update at 2022-07-25: 2022 ∙ 2021 ∙ 2020

Taro Pharmaceutical Industries Ltd. TARO

$ 42.45 -0.14%

Taro Pharmaceutical Industries Ltd. Financial Statements 2011-2024 | TARO

Annual Financial Statements Taro Pharmaceutical Industries Ltd.

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	1.36 B	1.83 B	2.73 B	4.19 B	3.58 B	4.21 B	5.23 B	5.26 B	4.35 B	2.36 B	1.72 B	1.23 B
Shares	37.6 M	38.2 M	38.5 M	39 M	40.2 M	41.3 M	42.8 M	42.8 M	44.3 M	44.7 M	44.6 M	44.5 M
Historical Prices	36	48.9	71.5	67.3	89.4	85.7	105	127	132	97.5	49.8	33.2
Net Income	58.3 M	-387 M	244 M	282 M	211 M	456 M	541 M	484 M	360 M	266 M	47.3 M	183 M
Revenue	561 M	549 M	645 M	670 M	662 M	879 M	951 M	863 M	759 M	671 M	145 M	506 M
Cost of Revenue	268 M	252 M	245 M	224 M	198 M	208 M	170 M	186 M	179 M	176 M	-	176 M
Gross Profit	293 M	297 M	400 M	446 M	464 M	672 M	781 M	677 M	580 M	495 M	99.2 M	330 M
Operating Income	63.5 M	-414 M	247 M	296 M	303 M	515 M	614 M	528 M	430 M	329 M	-	204 M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	609 K
EBITDA	89.4 M	-390 M	268 M	315 M	320 M	530 M	629 M	543 M	447 M	346 M	70.8 M	223 M
Operating Expenses	230 M	710 M	153 M	150 M	160 M	156 M	164 M	149 M	150 M	166 M	128 M	125 M
General and Administrative Expenses	57.1 M	52.8 M	56.8 M	90 M	88.2 M	85.7 M	92.4 M	87.6 M	91.7 M	86.4 M	23.1 M	93.9 M

All numbers in USD currency

Quarterly Income Statement Taro Pharmaceutical Industries Ltd.

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	-	-	-	-	-	-	-	37.9 M	-	-	-	38.3 M	-	-	-	38.5 M	-	-	-	39.4 M	-	-	-	40.5 M	-	-	-	42.8 M	-	-	-	42.8 M	-	-	-	42.8 M	-	-	-	44.8 M	-	-	-	44.5 M	44.5 M	-	-	44.3 M
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	47.3 M	-	-	-	25.7 M
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	145 M	-	-	-	108 M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	46 M	-	-	-	44.6 M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	99.2 M	-	-	-	63.1 M
Operating Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	66.2 M	-	-	-	33.4 M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-94 K	-	-	-	251 K
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	70.8 M	-	-	-	38.1 M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	32.9 M	-	-	-	29.7 M
General and Administrative Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8.74 M	-	-	-	22.5 M

All numbers in USD currency